TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.
News  ›  GlobeNewswire Inc.

AtaiBeckley Provides Update and Outlook for 2026 Ahead of J.P. Morgan Healthcare Conference

GlobeNewswire Inc. Logo GlobeNewswire Inc. • •By Ataibeckley Inc
AtaiBeckley Provides Update and Outlook for 2026 Ahead of J.P. Morgan Healthcare Conference

AtaiBeckley Inc (NASDAQ: ATAI), formed from the merger of atai Life Sciences and Beckley Psytech, announced its 2026 outlook ahead of the J.P. Morgan Healthcare Conference. The company reported positive Phase 2b data for BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression, with Phase 3 trials expected in Q2 2026. Additional milestones include Phase 2 data for VLS-01 (DMT buccal film) in H2 2026 and EMP-01 (oral R-MDMA) for social anxiety disorder in Q1 2026. The company completed its redomiciliation to the United States in December 2025 and was added to the NASDAQ Biotechnology Index.

Insights
VYLD   neutral

Participating in investment round as an institutional investor without additional context

ATAI   positive

Company demonstrated positive Phase 2b clinical trial results for lead candidate BPL-003 with rapid and durable antidepressant effects, announced advancement to Phase 3 trials, secured patent protection extending to 2043, completed strategic redomiciliation to improve operational efficiency, achieved inclusion in NASDAQ Biotechnology Index, and has sufficient financial runway through 2029. These developments indicate strong clinical progress and corporate momentum.

Keywords
#clinical-stage biotechnology #treatment-resistant depression #mental health treatments #Phase 2b clinical trial #Phase 3 trials #redomiciliation #NASDAQ Biotechnology Index #drug development pipeline

Tickers
ATAI
← Prev: Faraday Future Unveils Ambitious FX Super One Roadmap